RxDoctor Payments Data

Amina Haggag

Family Medicine · Northridge, CANPI 1518129972

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $1,800 of the $1,920 with a category attached, or 93.8%. E.r. Squibb & Sons, L.L.C. accounts for 93.8% of it on its own, with 1 other manufacturer making up the rest.

$1,920in general payments, 2019–2025

Across 2 payments — averaging $959.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$2K
  • AstraZeneca$120
$112,859,943in research payments, 2019–2025

Across 835 payments — averaging $135,162 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$38.6M
  • Eli Lilly$34.6M
  • Bristol Myers Squibb$15.9M
  • E.r. Squibb & Sons, L.L.C.$14.2M
  • Biogen$5.1M
  • CSL Behring$992K
  • plus $3.4M from 15 others

What the payments were for

  • Consulting fees$1,80094%
  • Food & beverage$1206%

General payments by program year

20
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
E.r. Squibb & Sons, L.L.C.1$1,800
AstraZeneca1$120

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,920 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California →

Other family medicine in Northridge

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →